This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva (TEVA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Merck (MRK) Beats on Q3 Earnings, Lags Sales, Ups EPS View
by Zacks Equity Research
Merck (MRK) beat estimates for earnings while missing the same for sales in third-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
J&J Intends to Buy Residual Stake in Japanese Skincare Firm
by Zacks Equity Research
Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q3 results on Oct 30.
Pfizer Succeeds in Pain Study, Forms JV to Make CNS Drugs
by Zacks Equity Research
Pfizer (PFE) and Lilly present detailed data from a phase III study on pain candidate, tanezumab. The former forms a new company for CNS treatment in alliance with Bain Capital.
Alkermes Boasts Strong Portfolio and Impressive Pipeline
by Zacks Equity Research
Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.
BMY vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. LLY: Which Stock Is the Better Value Option?
Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.
Novo Nordisk (NVO) Faces Pricing Pressure and Competition
by Zacks Equity Research
Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.
Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?
by Zacks Equity Research
Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
by Zacks Equity Research
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
3 Large-Cap Pharma Stocks Performing Better Than Industry
by Zacks Equity Research
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
This is Why Eli Lilly (LLY) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales
by Zacks Equity Research
Incyte's (INCY) performance is likely to be strong due to rising demand of lead drug, Jakafi.
Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for FLQL
Company News For Oct 5, 2018
by Zacks Equity Research
Companies In The News are: CLDR,HDP,BKS,LLLY,STZ
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
by Zacks Equity Research
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Lilly's Novel Diabetes Candidate Shows Promise in Phase II
by Zacks Equity Research
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.
Bull of the Day: Roche (RHHBY)
by Kevin Cook
With 3 of the top-ten cancer drugs globally, this Swiss giant is looking for the next I/O breakthroughs
Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies
by Zacks Equity Research
Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.
Merck & Other Pharma Players Await FDA Decisions in October
by Kinjel Shah
FDA grants approval to 41 new treatments till the end of September.
The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical
Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality
by Zacks Equity Research
Eli Lilly's (LLY) CGRP antibody Emgality injection gains an FDA approval for the preventive treatment of migraine in adults.